INNIO
As a key enabler and an integral part of the energy transition, today INNIO announced the launch of its “Ready for H2 ” portfolio that includes 100% hydrogen-fueled Jenbacher H2 -engines. INNIO’s “Ready for H2 ” gas engine portfolio is built on a long history of innovation with more than 30 years of experience and expertise in the use of renewable fuels and hydrogen-rich fuels, such as syngas and process gases for power generation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210721005146/en/
INNIO’s “Ready for H2 ” Portfolio
As of today, Jenbacher Type 4 gas engines – with an approximate output of 500 to 900 kilowatts (kW) - are available for operation with 100% hydrogen or mixtures of natural gas and hydrogen.
As of 2022, all other INNIO Jenbacher gas engines will be offered with a “Ready for H2 ” option, capable of running with up to 25% volume of hydrogen in pipeline gas and being able to be readily converted from natural gas to 100% hydrogen operation.
In addition, most of the currently installed INNIO Jenbacher natural gas fueled fleet can be upgraded to operate with up to 25% volume of hydrogen in pipeline gas or converted from natural gas to 100% hydrogen operation.
INNIO Jenbacher gas engines are uniquely positioned to deliver hydrogen power generation .
Building on decades of experience
Twenty years ago, the first Jenbacher 150 kW pilot engine ran on 100% hydrogen at a demonstration plant in northern Germany. Two decades later, in 2020, following several additional demonstration projects, INNIO and HanseWerk Natur collaborated on the application of industrial-scale hydrogen-fueled gas engines. The companies demonstrated a flagship project using variable hydrogen-natural gas mixes including 100% hydrogen on the world’s first 1-megawatt (MW) gas engine.
“I am proud of INNIO’s announcement of the first ‘Ready for H2 ’ product portfolio in the 200 kW – 10.4 MW power generation space. Our broad portfolio of innovative and fuel flexible Jenbacher gas engines - capable of operating on natural gas, carbon neutral biogas or hydrogen-rich fuels – are helping to pave the way to a greener energy future,” commented Carlos Lange, president and CEO of INNIO. “Jenbacher gas engines running on natural gas today can be converted to H2 operation when hydrogen becomes more readily available. This means that customers who invest in Jenbacher natural gas engines today, are also investing for the future.”
With about 90 hydrogen-rich fuel projects across 28 countries, INNIO has more than 30 years of experience with engines running on up to 70% volume of hydrogen in the fuel, yielding more than 250 MW. These installations can be found on all continents with various INNIO Jenbacher Type 2, Type 3, Type 4 and Type 6 gas engines.
The power of hydrogen
Green hydrogen, as an energy carrier for storage of volatile renewable energy, can store renewable energy for months or seasons. This will make renewable energy sources reliable and dispatchable and support the acceleration of fossil fuel replacement across the energy sector.
INNIO is committed to leading the deployment of H2 -engines which will facilitate the acceleration and transformation from fossil fuels to renewable energy sources. Typically, INNIO Jenbacher hydrogen-fueled gas engines will be operating in a combined heat and power configuration, achieving around 90% hydrogen fuel utilization.
###
In 2021, EcoVadis awarded INNIO Jenbacher a silver medal to honor its engagement for a climate-neutral, greener, and more secure energy future. This places INNIO Jenbacher in the top 17% of its peers working towards sustainability.
About INNIO
INNIO is a leading provider of renewable gas, natural gas, and hydrogen-based solutions and services for power generation and gas compression at or near the point of use. With our Jenbacher and Waukesha gas engines, INNIO helps to provide communities, industry and the public access to sustainable, reliable and economical power ranging from 200 kW to 10 MW. We also provide life-cycle support and digital solutions to the more than 53,000 delivered gas engines globally, through our service network in more than 100 countries. We deliver innovative technology driven by decarbonization, decentralization, and digitalization to help lead the way to a greener future. Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, U.S. For more information, visit the company's website at www.innio.com . Follow INNIO on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210721005146/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press release
Through the Extreme Exchange (IX) acquisition, Megaport gains seven Internet Exchanges and access to 40+ data centres across India’s fastest-growing digital hubs. Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly thr
IonQ and QuantumBasel Expand Long-Term Partnership in Next-Generation Quantum Systems17.12.2025 22:10:00 CET | Press release
Extension solidifies QuantumBasel as IonQ’s Innovation Center in Europe; adds IonQ Tempo and next-generation system to advance quantum commercialization IonQ (NYSE: IONQ), the world’s leading quantum company, today announced an expanded agreement with QuantumBasel, the quantum initiative of uptownBasel, Switzerland’s innovation campus. The extended contract grants QuantumBasel ownership of its existing IonQ Forte Enterprise system and secures ownership of a next-generation Tempo system. This new agreement brings the total deal value of the QuantumBasel and IonQ partnership to over $60 million and extends IonQ’s on-site presence in Switzerland four more years, continuing through 2029. QuantumBasel is IonQ’s official Innovation Center in Europe, serving as a hub for European industry, academia, and research institutions to explore practical quantum computing applications and access IonQ’s latest enterprise-grade systems. “Our extended partnership with QuantumBasel represents a cornerston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom